Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in Taiwan as part of the expansion phase of its THIO-101 Phase 2 trial. The trial is focused on evaluating ateganosine (THIO) for advanced non-small cell lung cancer (NSCLC) in patients who have been heavily pre-treated and have previously failed treatment with checkpoint inhibitors and chemotherapy. This expansion marks a significant milestone, allowing access to a larger patient pool across Europe and Asia. The trial includes two treatment arms: ateganosine sequenced with cemiplimab (Libtayo®) and ateganosine monotherapy, with Regeneron supplying Libtayo for the combination cohort. As of May 15, 2025, the median overall survival for the 22 patients in the third-line treatment was reported as 17.8 months. The treatment has been generally well-tolerated. Further results from the study will be presented as the trial progresses.